Craft

Lotus Pharmaceutical

Stock Price

NT$254

2024-10-29

Market Capitalization

NT$66.7 B

2024-10-29

Revenue

NT$20.5 B

FY, 2025

Lotus Pharmaceutical Summary

Company Summary

Overview
Lotus Pharmaceutical (美時化學製藥股份有限公司) is a company that develops, manufactures, and markets pharmaceutical products. It provides generic drugs covering CNS, CVS, oncology, women's health, and anti-obesity treatments in tablet and capsule forms. The company also specializes in contract manufacturing and contract research services for the pharmaceutical and biotechnology industries.
Type
Public
Status
Active
Founded
1966
HQ
Taipei City, TW | view all locations
Website
https://www.lotuspharm.com/
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key People

  • Petar Vazharov
  • Manish Chawla

    Manish Chawla, VP of R&D

    • Bjartur Shen

      Bjartur Shen, Strategies and Finance VP

      • Eeling Chan

      LocationsView all

      6 locations detected

      • Taipei City, Taipei City HQ

        Taiwan

        17F, No. 277, Songren Road, Xinyi District

      • Shanghai Shi

        China

        Hongqiao Railway Station metro station, Minhang Qu

      • Singapore

        Singapore

        80 Robinson Rd, #02-00

      • Krung Thep Maha Nakhon

        Thailand

        1126/2 Phetchaburi Rd, Khwaeng Makkasan, Khet Ratchathewi

      • Ho Chi Minh City, Thành phố Hồ Chí Minh

        Viet Nam

        No. 245/2/32 Binh Loi street, Ward 13

      Lotus Pharmaceutical Financials

      Summary Financials

      Revenue (Q1, 2026)
      NT$8.6B
      Gross profit (Q1, 2026)
      NT$5.0B
      Net income (Q1, 2026)
      NT$567.2M
      Cash (Q1, 2026)
      NT$6.2B
      EBIT (Q1, 2026)
      NT$2.0B
      Enterprise value
      $108.4B

      Footer menu